ixPeptide® based first-in-class medicines and diagnostics for autoimmune & genetic diseases

ixPeptides® form stable, tunable, predictable molecular surfaces with short chain-lengths. These properties combine the benefits and eliminate the drawbacks of small molecules and large antibodies.

Contact Us

Our Mission

Discover, develop and commercialise smartpeptide based medicines and diagnostics to treat patients with autoimmune and genetic diseases with the greatest unmet medical needs where current therapies are inadequate.

Contact Us

Our approach

The ixPeptide® Platform - the breakthrough molecular solution for the custom design of self-assembling polypeptides. It increases the drug-likeness of the peptide molecules and creates first-in-class medicines to treat patients with major unmet clinical needs.

Ladon Therapeutics

Ladon Therapeutics is a clinical stage biopharmaceutical company. Ladon Therapeutics brings together breakthrough peptide chemistry and a state of the art diagnostic laboratory from gene expression profiling to in vivo disease models to characterize, test and evaluate ixPeptide® drug candidates.

What we do

Ladon Therapeutics discovers, develops and commercializes ixPeptide® based first-in-class medicines and diagnostics to treat patients with autoimmune and genetic diseases with major unmet medical needs.

Our Vision

Our vision is to be a pioneering bio-pharmaceutical company that makes breakthrough scientific innovations happen to become cures for debilitating diseases.

Core Values

Aiming High

Discover and Develop a new generation of smart peptide based therapies

Inclusion

Discover and Develop a new generation of smart peptide based therapies

Excellence

Discover and Develop a new generation of smart peptide based therapies

Teamwork

Discover and Develop a new generation of smart peptide based therapies

The ixPeptide® Platform

The ixPeptide® Platform is a breakthrough molecular solution to increase the “druggability” potential of peptidic compounds.Pharmacologically active peptides are a unique class of compounds with molecular weights from 300 to 5000 Da.They are considered as linear polymers of natural and/or artificial amino acids.

Who we are

Gábor Heltovics
Chief Executive Officer
LinkedIn
István Mándity
Lead Advisor – Peptide Chemistry
LinkedIn
József Maléth
Chief Scientific Officer
LinkedIn
Beáta Mándityné Huszka
Head of Peptide Chemistry Laboratory
LinkedIn
Petra Pallagi
Head of Pre-clinical Research
LinkedIn

Who we are

Ladon Therapeutics is a clinical stage biopharmaceutical company

Featured news

10 November 2022
Technology
Our Vision

Our vision is to be a pioneering bio-pharmaceutical company that makes breakthrough scientific innovations happen to become cures for debilitating diseases.

10 November 2022
Our Vision

Our vision is to be a pioneering bio-pharmaceutical company that makes breakthrough scientific innovations happen to become cures for debilitating diseases.

10 November 2022
Our Vision

Our vision is to be a pioneering bio-pharmaceutical company that makes breakthrough scientific innovations happen to become cures for debilitating diseases.

10 November 2022
Our Vision

Our vision is to be a pioneering bio-pharmaceutical company that makes breakthrough scientific innovations happen to become cures for debilitating diseases.

10 November 2022
Our Vision

Our vision is to be a pioneering bio-pharmaceutical company that makes breakthrough scientific innovations happen to become cures for debilitating diseases.

10 November 2022
Our Vision

Our vision is to be a pioneering bio-pharmaceutical company that makes breakthrough scientific innovations happen to become cures for debilitating diseases.

October 25, 2021
Technology
Megkezdődött a„Proteomimetikus peptid gyógyszerek fejlesztése és gyártása nagyáteresztő képességű innovatív platformon” című pályázat2020-1.1.5-GYORSÍTÓSÁV-2021-00009

Megkezdődött a„Proteomimetikus peptid gyógyszerek fejlesztése és gyártása nagyáteresztő képességű innovatív platformon” című pályázat2020-1.1.5-GYORSÍTÓSÁV-2021-00009

July 20, 2020
Technology
CalciMedica and EpiPharma Enter into Research Collaboration to Discoverand Develop CRAC Channel Inhibitor Therapies

Ready to make the first step towards your new future?

We’re here to help.

Contact Us